In our previous clinical study of treatment of subjects with overweight and obesity with tRES + HESP, the pharmacological target validation of the Nrf2-dependent induction of increased Glo1 expression and activity was achieved [39]. This evidence concerns the gene GLO1 and obesity disorder.